USFDA4 Feb 2026, 11:22 am
Cohance Lifesciences Ltd. Receives Warning Letter from USFDA for Nacharam Facility
AI Summary
Cohance Lifesciences Ltd. has received a Warning Letter from the USFDA for their Nacharam formulation facility. This follows an earlier communication where the facility was classified as Official Action Indicated (OAI). The facility contributes less than 2% of consolidated revenues and related EBITDA contribution is below 1%. The company is committed to addressing the concerns raised by the USFDA and maintaining high standards of quality and regulatory compliance.
Key Highlights
- Cohance Lifesciences Ltd. receives Warning Letter from USFDA for Nacharam facility
- Nacharam facility was previously classified as Official Action Indicated (OAI)
- Facility contributes less than 2% of consolidated revenues and related EBITDA contribution is below 1%
- Company committed to addressing USFDA concerns and maintaining high standards of quality and regulatory compliance